Insulin efsitora alfa

DB19013InvestigationalProtein Based Therapies

Insulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting...

Mechanism: Pharmacologically active on Insulin receptor
Curator reviewed
First approval: United States, 2026
Also known as: Insulin efsitora
Code names: LY-3209590

Resolves to

Compound

UNIIOZ465SMQ28CAS2131038-11-2

Targets

P06213INSR

What you can answer from here — as of September 29, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

2Marketed productsAcross 1 country and 1 labeller

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Insulin efsitora alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account